Tag

Oncopeptides

Jakob Lindberg

Oncopeptides rescinds voluntary withdrawal of Pepaxto in the US

January 24, 2022

The company has contacted the …

Klaas Bakker

Oncopeptide study published in the Lancet

January 20, 2022

Data from the phase 3 …

Jakob Lindberg

He is the new CEO of Oncopeptides

November 15, 2021

The Board of Directors has …

CFO

Oncopeptides appoints new interim CFO

November 9, 2021

Oncopeptides has appointed Annika Muskantor …

Klaas Bakker

Oncopeptides reduces the activity level in the development program of melflufen

November 6, 2021

Oncopeptides has decided to reduce …

Oncopeptides withdraws Pepaxto in the US and scales down its organization

October 23, 2021

Oncopeptides has announced that the …

Marty Duvall

Oncopeptides announces regulatory update from the FDA

August 2, 2021

The US Food and Drug …

pipette

Oncopeptides’ announces updated trial results

July 13, 2021

Oncopeptides has announced updated results …

Klaas Bakker

Oncopeptides announces results from the OCEAN study

June 6, 2021

Oncopeptides have announced positive results …

Marty Duvall

Oncopeptides submits application for conditional marketing authorization of melflufen in the EU

April 19, 2021

Oncopeptides has submitted an application …

Marty Duvall

Oncopeptides’ PEPAXTO included in new Multiple Myeloma guidelines

March 23, 2021

Oncopeptides announces that PEPAXTO (melphalan …

Andrea Passalacqua

Oncopeptides strengthens its leadership teams

March 10, 2021

Oncopeptides strengthens the leadership of …

Jakob Lindberg

Oncopeptides receives FDA approval

March 1, 2021

FDA has approved Oncopeptides’ PEPAXTO …

Klaas Bakker

Oncopeptides enrolls the first patient in phase 3 study

January 8, 2021

Oncopeptides has announced that the …

Marty Duvall

Oncopeptides has submitted an IND application to FDA

October 21, 2020

Oncopeptides has submitted an Investigational …

Anders Martin-Löf

Oncopeptides signs 40 million EUR loan agreement

October 19, 2020

Oncopeptides has entered into a …

1
2
3